Clinical Trial Update: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. [Phase 2]

View source ↗

Summary

Phase II trial of NPB-01 in anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder has completed; the document’s wording suggests the combina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• NPB-01

Snippet

Sponsor: Nihon Pharmaceutical Co., Ltd | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 2 | Status: COMPLETED